Which has better earnings & valuation, RNA or AURA?

Avidity Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences N/A N/A N/A -$0.97 N/A Aura Biosciences N/A N/A -$106.19M -$1.75 N/A

Is RNA or AURA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A Aura Biosciences N/A -73.18% -62.00%

Does the media refer more to RNA or AURA?

In the previous week, Aura Biosciences had 13 more articles in the media than Avidity Biosciences. MarketBeat recorded 29 mentions for Aura Biosciences and 16 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.81 beat Aura Biosciences' score of 0.44 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RNA or ACRS?

In the previous week, Avidity Biosciences had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Avidity Biosciences and 13 mentions for Aclaris Therapeutics. Avidity Biosciences' average media sentiment score of 0.81 beat Aclaris Therapeutics' score of 0.07 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, RNA or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences N/A N/A N/A -$0.97 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is RNA or CLYM more profitable?

Avidity Biosciences' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A Climb Bio N/A -31.79% -30.79%

Does the media refer more to RNA or CLYM?

In the previous week, Avidity Biosciences had 8 more articles in the media than Climb Bio. MarketBeat recorded 16 mentions for Avidity Biosciences and 8 mentions for Climb Bio. Avidity Biosciences' average media sentiment score of 0.81 beat Climb Bio's score of 0.76 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MNPR or RNA?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A Avidity Biosciences N/A N/A N/A -$0.97 N/A

Is MNPR or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Monopar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% Avidity Biosciences N/A N/A N/A

Does the media refer more to MNPR or RNA?

In the previous week, Monopar Therapeutics had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 26 mentions for Monopar Therapeutics and 16 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.81 beat Monopar Therapeutics' score of 0.21 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Avidity Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNA or DBVT?

In the previous week, Avidity Biosciences had 14 more articles in the media than DBV Technologies. MarketBeat recorded 16 mentions for Avidity Biosciences and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.23 beat Avidity Biosciences' score of 0.81 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avidity Biosciences (RNA) Competitors

$12.96 +0.12 (+0.93%)

As of 08/17/2026 04:00 PM Eastern

Compare

RNA vs. AURA, ACRS, CLYM, MNPR, and DBVT

Should you buy Avidity Biosciences stock or one of its competitors? Avidity Biosciences's main competitors and comparable companies include Aura Biosciences (AURA), Aclaris Therapeutics (ACRS), Climb Bio (CLYM), Monopar Therapeutics (MNPR), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avidity Biosciences compare to Aura Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

96.8% of Aura Biosciences shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aura Biosciences had 13 more articles in the media than Avidity Biosciences. MarketBeat recorded 29 mentions for Aura Biosciences and 16 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.81 beat Aura Biosciences' score of 0.44 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avidity Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$0.97	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Avidity Biosciences' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Aura Biosciences	N/A	-73.18%	-62.00%

Avidity Biosciences presently has a consensus target price of $63.85, suggesting a potential upside of 392.64%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 127.86%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avidity Biosciences is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Avidity Biosciences beats Aura Biosciences on 8 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to Aclaris Therapeutics?

Avidity Biosciences (NASDAQ:RNA) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Avidity Biosciences currently has a consensus price target of $63.85, suggesting a potential upside of 392.64%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 94.26%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Avidity Biosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Avidity Biosciences' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Avidity Biosciences has higher earnings, but lower revenue than Aclaris Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$0.97	N/A
Aclaris Therapeutics	$7.83M	105.71	-$64.92M	-$0.58	N/A

In the previous week, Avidity Biosciences had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Avidity Biosciences and 13 mentions for Aclaris Therapeutics. Avidity Biosciences' average media sentiment score of 0.81 beat Aclaris Therapeutics' score of 0.07 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aclaris Therapeutics beats Avidity Biosciences on 7 of the 13 factors compared between the two stocks.

How does Avidity Biosciences compare to Climb Bio?

Avidity Biosciences (NASDAQ:RNA) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Avidity Biosciences' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Climb Bio	N/A	-31.79%	-30.79%

Avidity Biosciences currently has a consensus price target of $63.85, suggesting a potential upside of 392.64%. Climb Bio has a consensus price target of $22.75, suggesting a potential upside of 30.45%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Avidity Biosciences had 8 more articles in the media than Climb Bio. MarketBeat recorded 16 mentions for Avidity Biosciences and 8 mentions for Climb Bio. Avidity Biosciences' average media sentiment score of 0.81 beat Climb Bio's score of 0.76 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Climb Bio shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Climb Bio is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$0.97	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Avidity Biosciences and Climb Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Avidity Biosciences' return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Avidity Biosciences	N/A	N/A	N/A

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Monopar Therapeutics currently has a consensus target price of $118.67, suggesting a potential upside of 1.87%. Avidity Biosciences has a consensus target price of $63.85, suggesting a potential upside of 392.64%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Avidity Biosciences	N/A	N/A	N/A	-$0.97	N/A

In the previous week, Monopar Therapeutics had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 26 mentions for Monopar Therapeutics and 16 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.81 beat Monopar Therapeutics' score of 0.21 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Avidity Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monopar Therapeutics and Avidity Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to DBV Technologies?

Avidity Biosciences (NASDAQ:RNA) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Avidity Biosciences had 14 more articles in the media than DBV Technologies. MarketBeat recorded 16 mentions for Avidity Biosciences and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.23 beat Avidity Biosciences' score of 0.81 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.7% of DBV Technologies shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avidity Biosciences currently has a consensus price target of $63.85, indicating a potential upside of 392.64%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 230.61%. Given Avidity Biosciences' higher possible upside, equities research analysts clearly believe Avidity Biosciences is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Avidity Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Avidity Biosciences' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Avidity Biosciences has higher earnings, but lower revenue than DBV Technologies. Avidity Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$0.97	N/A
DBV Technologies	$5.64M	163.55	-$146.95M	-$3.51	N/A

Summary

Avidity Biosciences and DBV Technologies tied by winning 6 of the 12 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$219.64M	$3.73B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.56%	10.62%
P/E Ratio	-13.36	11.49	270.85	25.39
Price / Sales	N/A	1,165.64	559.91	70.90
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	N/A	17.19	11.06	6.51
Net Income	N/A	-$13.19M	$3.45B	$347.22M
7 Day Performance	5.62%	0.95%	0.62%	1.27%
1 Month Performance	6.67%	2.67%	2.08%	2.72%
1 Year Performance	-70.86%	54.03%	61.59%	21.85%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	2.6294 of 5 stars	$12.96 +0.9%	$63.85 +392.6%	-72.1%	$219.64M	N/A	N/A	190	Earnings Report Analyst Revision
AURA Aura Biosciences	2.0098 of 5 stars	$7.70 -3.6%	$20.50 +166.2%	+14.3%	$826.46M	N/A	N/A	50	Earnings Report Analyst Downgrade
ACRS Aclaris Therapeutics	2.0636 of 5 stars	$5.90 -0.2%	$11.50 +94.9%	+216.6%	$826.36M	$7.83M	N/A	100
CLYM Climb Bio	2.4181 of 5 stars	$13.54 -3.3%	$22.75 +68.0%	+817.9%	$804.11M	N/A	N/A	9
MNPR Monopar Therapeutics	1.5808 of 5 stars	$116.35 -2.4%	$112.08 -3.7%	+226.2%	$798.59M	N/A	N/A	10	Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. AURA, ACRS, CLYM, MNPR, and DBVT

How does Avidity Biosciences compare to Aura Biosciences?

Summary

How does Avidity Biosciences compare to Aclaris Therapeutics?

Summary

How does Avidity Biosciences compare to Climb Bio?

Summary

How does Avidity Biosciences compare to Monopar Therapeutics?

Summary

How does Avidity Biosciences compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. AURA, ACRS, CLYM, MNPR, and DBVT

How does Avidity Biosciences compare to Aura Biosciences?

Do insiders & institutionals believe in RNA or AURA?

Does the media refer more to RNA or AURA?

Which has better earnings & valuation, RNA or AURA?

Is RNA or AURA more profitable?

Do analysts prefer RNA or AURA?

Summary

How does Avidity Biosciences compare to Aclaris Therapeutics?

Do analysts prefer RNA or ACRS?

Is RNA or ACRS more profitable?

Which has higher valuation and earnings, RNA or ACRS?

Does the media favor RNA or ACRS?

Do insiders and institutionals hold more shares of RNA or ACRS?

Summary

How does Avidity Biosciences compare to Climb Bio?

Is RNA or CLYM more profitable?

Do analysts recommend RNA or CLYM?

Does the media refer more to RNA or CLYM?

Do institutionals and insiders hold more shares of RNA or CLYM?

Which has preferable valuation and earnings, RNA or CLYM?

Summary

How does Avidity Biosciences compare to Monopar Therapeutics?

Is MNPR or RNA more profitable?

Do institutionals and insiders hold more shares of MNPR or RNA?

Do analysts recommend MNPR or RNA?

Which has stronger earnings & valuation, MNPR or RNA?

Does the media refer more to MNPR or RNA?

Summary

How does Avidity Biosciences compare to DBV Technologies?

Does the media refer more to RNA or DBVT?

Do institutionals and insiders have more ownership in RNA or DBVT?

Do analysts prefer RNA or DBVT?

Is RNA or DBVT more profitable?

Which has preferable earnings & valuation, RNA or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools